Skye: Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical

Skye Bioscience (NASDAQ: SKYE) has announced promising preclinical results for its CB1 antibody, nimacimab, in treating obesity. In a diet-induced obesity model, the combination of nimacimab with tirzepatide achieved over 30% weight loss after 25 days of treatment. Nimacimab alone demonstrated 23.5% weight loss, comparable to monlunabant and tirzepatide monotherapies.

New in vitro data revealed nimacimab's superior potency characteristics through its non-competitive allosteric binding to CB1, showing stable effectiveness even under high agonist concentrations, unlike monlunabant. This differentiated mechanism suggests potential advantages in treating obesity without the neuropsychiatric side effects associated with small molecule CB1 inhibitors.

The company expects to release top-line randomized data from the Phase 2a CBeyond™ study in late Q3/early Q4 2025.

https://www.stocktitan.net/news/SKYE/skye-bioscience-demonstrates-over-30-weight-loss-with-nimacimab-and-mb2jcjfu6uwp.html